List of Ingrezza drug patents

Ingrezza is owned by Neurocrine.

Ingrezza contains Valbenazine Tosylate.

Ingrezza has a total of 20 drug patents out of which 0 drug patents have expired.

Ingrezza was authorised for market use on 11 April, 2017.

Ingrezza is available in capsule;oral dosage forms.

Ingrezza can be used as method of treating tardive dyskinesia while avoiding concomitant use of a strong cyp3a4 inducer; treatment of tardive dyskinesia, treatment of tardive dyskinesia; method of administering valbenazine while avoiding concomitant use of a strong cyp3a4 inducer, treatment of tardive dyskinesia.

Drug patent challenges can be filed against Ingrezza from April, 2021.

The generics of Ingrezza are possible to be released after 10 August, 2040.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8039627 NEUROCRINE Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto
Apr, 2031

(8 years from now)

US10065952 NEUROCRINE Valbenazine salts and polymorphs thereof
Oct, 2036

(13 years from now)

US10844058 NEUROCRINE Valbenazine salts and polymorphs thereof
Oct, 2036

(13 years from now)

US10851103 NEUROCRINE Valbenazine salts and polymorphs thereof
Oct, 2036

(13 years from now)

US10851104 NEUROCRINE Valbenazine salts and polymorphs thereof
Oct, 2036

(13 years from now)

US10919892 NEUROCRINE Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
Dec, 2036

(13 years from now)

US10906903 NEUROCRINE Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1,-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
Dec, 2036

(13 years from now)

US10906902 NEUROCRINE Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1,-a]isoquinolin-2-2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
Dec, 2036

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8357697 NEUROCRINE Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto
Nov, 2027

(4 years from now)

US11040029 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Oct, 2037

(14 years from now)

US10912771 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Oct, 2037

(14 years from now)

US10993941 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Oct, 2037

(14 years from now)

US10857148 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Oct, 2037

(14 years from now)

US10874648 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Oct, 2037

(14 years from now)

US10857137 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Oct, 2037

(14 years from now)

US10952997 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Oct, 2037

(14 years from now)

US11026939 NEUROCRINE High dosage valbenazine formulation and compositions, methods, and kits related thereto
Sep, 2038

(15 years from now)

US11311532 NEUROCRINE High dosage valbenazine formulation and compositions, methods, and kits related thereto
Sep, 2038

(15 years from now)

US11026931 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Aug, 2039

(16 years from now)

US10940141 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors
Aug, 2040

(17 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 11, 2022

Drugs and Companies using VALBENAZINE TOSYLATE ingredient

NCE-1 date: April, 2021

Market Authorisation Date: 11 April, 2017

Treatment: Treatment of tardive dyskinesia; Method of treating tardive dyskinesia while avoiding concomitant use of a strong cyp3a4 inducer; Method of administering valbenazine while avoiding concomitant use of a strong cyp3a4 inducer

Dosage: CAPSULE;ORAL

How can I launch a generic of INGREZZA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in